Does HLA matching matter in the modern era of renal transplantation?

Jon Jin Kim 1,2, Susan V Fuggle 3,4, Stephen D Marks 5,6

Abstract

Children with end-stage kidney disease should be offered the best chance for future survival which ideally would be a well-matched pre-emptive kidney transplant. Paediatric and adult practice varies around the world depending on geography, transplant allocation schemes and different emphases on living (versus deceased) donor renal transplantation. Internationally, paediatric patients often have priority in allocation schemes and younger donors are preferentially allocated to paediatric recipients. HLA matching can be difficult and may result in longer waiting times. Additionally, with improved surgical techniques and modern immunosuppressive regimens, how important is the contribution of HLA matching to graft longevity? In this review, we discuss the relative importance of HLA matching compared with donor quality; and long-term patient outcomes including re-transplantation rates. We share empirical evidence that will be useful for clinicians and families to make decisions about best donor options. We discuss why living donation still provides the best allograft survival outcomes and what to do in the scenario of a highly mismatched living donor.

Keywords Human leukocyte antigens · Matching · Mismatching · Living donors · Deceased donors · Kidney transplantation

Introduction

The first successful kidney transplant was performed in 1954 and was possible because of the perfect genetic match between the Herrick brothers who are identical twins [1]. At around the same time, the proteins that differentiate self from non-self were identified and called the human leukocyte antigens (HLA) [2]. Detection of antibodies against donor HLA using the cell-dependent cytotoxicity (CDC) crossmatch, published by Terasaki in 1969, reduced the rates of hyperacute rejection and made transplantation safer [3]. The subsequent development of immunosuppression, initially with corticosteroids and azathioprine, enabled transplantation to be a long-term therapeutic viability. However, immunosuppression has become more effective (with the introduction of ciclosporin, tacrolimus and mycophenolate mofetil in the 1990s and subsequently with induction agents, such as basiliximab). This together with improved surgical techniques has resulted in improved patient and renal allograft survival outcomes [4]. Currently, the expected 5-year survivals of paediatric living and deceased donor kidney transplants are > 85% and > 75% respectively [5, 6]. We therefore question whether HLA matching is still relevant in the modern transplant era.

The major histocompatibility complex (MHC) is located on a large 4Mbp portion of chromosome 6p21 and encodes the HLA proteins [7]. HLA are essential for differentiation of self from non-self and the extensive polymorphism of HLA has been maintained throughout evolution. The conventional classification divides HLA into class I and class II. HLA class I (HLA-A, B and C) are expressed on nearly all nucleated cells and load anomalous peptides (e.g. viral peptides) on MHC class I and signal to CD8 T cells for killing. HLA class
II (HLA-DR, DQ and DP) are located on professional antigen-presenting cells (APC), in particular dendritic cells and B cells, which can sense antigens, engulf, process and load the antigens to activate CD4 T cells. Therefore, the genetic polymorphism is important to ensure presentation of a wide repertoire of foreign antigens. This in turn presents a significant barrier to transplantation and underlies the process of rejection. Of note, the name HLA is a misnomer as they serve an important natural role and as such are not antigens for the body’s immune system.

**Lessons from registries**

Human leukocyte antigens matching has been at the forefront of transplantation so there are no randomised controlled trials studying its role. Geography is important to consider in this context as cold ischaemia times would be increased in large countries if deceased donor organs were travelling huge distances, whereas HLA matching is prioritised in the UK, which is a relatively small country. These practical considerations and the relative size of deceased donor programs are reflected in the different practices of organ allocation policies around the world [8]. Having a larger deceased donor pool would increase flexibility in donor allocation criteria. In certain countries however, deceased donor programs have not been set-up and the only option would therefore be living donation.

Paediatric patients who have pre-emptive transplantation unequivocally have better patient and renal allograft survival compared with dialysis-exposed patients [9]. This effects both living and deceased donation; and survival decreases as dialysis times go over 1 year. Patients who are pre-emptively transplanted have different demographics though, with a higher proportion of structural defects, higher proportion of white non-Hispanics and lower social deprivation. Nonetheless, the registry data support policies to improve earlier detection of kidney disease and streamlined pathways to access transplantation.

The evidence behind HLA matching derives from macro-level population studies from national and multi-national registries. There are caveats from interpreting registry results including quality of registry data (e.g. data completeness, accuracy and co-variates) and methodology for data analysis (e.g. pre-specified hypotheses and co-variates, statistical analysis and comparator groups) [10]. Data from some registries do not include all clinical events over time such as rejection or changes in treatment. Most national registries mandate data collection although it is difficult to compare the results due to different patient populations, healthcare systems and data collection methods (see Table 1) [11, 12].

The United Network for Organ Sharing (UNOS) registry in the USA contains one of the largest and oldest sets of patients. An early report looking at the period from 1987 to 1998 (8422 patients under 21 years) showed a large centre effect without statistically significant difference in renal allograft survival due to HLA mismatch (MM) [13]. A later cohort from 1994 to 2004 (9358 patients under 21 years) in the modern immunosuppression era was investigated for the effects of HLA matching and donor age [14]. Overall, the risk of allograft loss increased with higher MM for both deceased donor (DD) and living donor (LD) transplants. Older donors classified as ≥ 45 years were associated with worse outcomes in DD but there was no association found in LD (Fig. 1). This study was unique as estimated socioeconomic status was included as a variable but did not reach statistical significance in the final model. Williams et al. recently analysed the entire cohort from 1987 to 2016 with a total of 18,602 patients under 18 years of age [15]. There was a strong effect of transplant era and recipient age. Recipients in the oldest fourth quartile (from 15 to 18 years) had a hazard ratio (HR) of 1.76 compared with the lowest quartile (0 to 7 years) and the HR increased with each age quartile. The fully adjusted co-variate model also included donor details, underlying diagnosis and discharge immunosuppression. Risk of allograft loss increased with each HLA MM in a linear order for both LD and DD. There was a 16% higher risk of allograft loss for 1 MM in DD and 62% for 5 and 6 MM. The size effect of MM was higher in LD with 48% for 1 MM and 114% for 6 MM though overall survival rates of LD transplants were as long or longer than DD. The number of LD with 4 to 6 MM was smaller, as expected, as the majority of LD were haplotype matched parents.

Similar results are obtained when examining other worldwide registries. The Collaborative Transplant Study (CTS) is a worldwide co-operative effort with input from 42 countries. Opelz and Döhler analysed the cohort from 1988 to 2007 which included 9209 patients under 18 years of age [16]. The analysis was stratified into two decades, 1988 to 1997 and 1998 to 2007, with consistently better outcomes in the latter era. Patients with 4 to 6 MM had an HR of allograft loss of 1.19 (95% confidence interval, CI 1.08–1.32) compared with 0 to 3 MM in the early decade and this was similar in the second decade (HR 1.26, p = 0.009) despite better immunosuppression. A more recent analysis was performed for patients from 2000 to 2015 (3627 LD only transplants) [17]. Compared with 0 MM LD (most likely fully matched siblings), the group of 1 to 3 MM had an HR of 2.2 (CI 1.39–3.49) and 4 to 6 MM had an HR of 3.91 (CI 2.37–6.45). Therefore, the effect of HLA MM in LD was clustered into two groups, 1 to 3 MM and 4 to 6 MM, which follows donor-recipient relationship categories, i.e. haplotype matched first-degree relatives (mostly parents) and non-haplotype matched donors (living related or unrelated). Haplotype matched donors will also have benefits of matching additional minor histocompatibility antigens (non-HLA polymorphisms able to elicit an immune response). The HR of HLA MM in this study is high as the reference group was the full 0 MM LD. Fully
Table 1  Summary of main papers from registries around the world. This is not meant as a critique but highlights the different approaches and results from each paper

| Author, registry | Year, number of patients | Research question | Co-variates | Main results | Ref |
|------------------|--------------------------|-------------------|-------------|--------------|-----|
| Gritsch (2008), OPTN | 1996–2004, 2292 DD < 18 years | HLA-DR MM and donor age | 1 1 √ √ √ √ √ √ | Allograft survival at 5 years was similar for each HLA-DR MM. Donors > 35 years of age had worse survival. | 31 |
| Opelz (2010), CTS | 1998–2007, 9209 < 18 years | HLA MM and donor age | 1 1 √ √ √ √ √ √ | Survival rates were similar for donors up until the age of 49. HLA MM increases risk of graft failure in a hierarchical manner and this effect persisted with modern immunosuppression. PTLD is associated with two HLA-DR MM. | 16 |
| Foster (2013), USRD | 1994–2004, FU 2009 9358 < 21 years | Relative importance of HLA MM and donor age | 1 1 √ √ √ √ √ | HLA MM and donor age associated with DD survival. Advantages of younger donors (< 35 years) offset poor HLA MM. Donors > 45 years with 0–1 MM had similar survival to younger donors. Older LD with poor HLA MM had similar outcomes to DD. | 14 |
| Marlais (2016), UKTR | 2000–2011, 1378 < 18 years | HLA MM | 1 √ √ √ √ √ | Kidney allograft survival is incrementally associated with HLA MM for DD and LD. 0–3 MM DD survival is equivalent to 4–6 MM LD. | 15 |
| Opelz (2017), CTS | 2000–2015, 3627 < 18 years | HLA MM | 1 √ √ √ √ | Graft loss of DD was consistently higher than LD at all time points. Both age difference and HLA MM were incrementally associated with graft loss. | 19 |

A, donor age; B, HLA MM; C, recipient demographics including age, sex and race; D, primary renal disease; E, donor demographics including race 1, variable that is addressed as question in the study (excluding age); F, transplant era or year; G, cold ischaemic time; H, panel reactive antibodies; I, duration of dialysis or pre-emptive transplantation; J, immunosuppression; K, socioeconomic status
matched siblings represent the closest to a perfect match which would be identical twins. In the UK Transplant Registry cohort of 1378 patients from 2000 to 2011, worse allograft outcomes were associated with poorer HLA matching with HLA matching performed using a tier system [18]. In the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA), adjusted HR increased 20% for each HLA MM in the 1134 patients analysed from 1990 to 2015 [19]. Therefore, as a whole, HLA MM significantly increases the risk of graft failure for both groups of LD and DD recipients. The risks are incremental for each HLA MM for DD. The risks tend to group according to the relationship to the donors for LD (haplotype matched parents/siblings or non-haplotype matched donors).

Comparing HLA class I and class II

The evidence of an HLA loci effect is contentious with conflicting results comparing HLA-A versus HLA-B versus HLA-DR or HLA class I versus class II. Evidence for deleterious effects of HLA-DR MM came from older studies [20]. HLA class II had no statistically significant effect on 5-year outcomes in the modern immunosuppression era (post-1994) in the CTS report [16]. Williams et al. also found no effect when comparing all 27 permutations of HLA MM. The authors concluded that the effect of HLA MM is therefore additive and does not depend on particular HLA loci [15].

More recently, long-term allograft loss is often associated with antibody-mediated rejection (ABMR). ABMR is more prevalent amongst HLA class II antibodies, and in particular HLA-DQ [21, 22]. The target for HLA class II antibodies is being debated although biopsies show evidence of microcirculatory inflammation. It has been long known that vascular endothelial cells and renal tubules can upregulate MHC class II during inflammation [23–25]. Nocera et al. published an elegant study eluting HLA antibodies from kidney biopsies [26]. HLA antibodies in the graft were only detected in the presence of serum HLA antibodies and were of identical HLA specificities. Graft HLA antibodies were again predominantly HLA class II (76%), compared with 24% HLA class I. It is not clear if the eluted graft antibodies were produced by intra-graft plasma B cells or from circulating or lymphoid B cells.

If HLA class II MM drives ABMR, why is allograft outcome not worse with HLA class II MM in registry studies? This could be due to inherent methodological limitations that cannot take into account the interaction between HLA class I and class II antibodies. In addition, HLA-DQ MM is currently not consistently recorded. On many occasions when HLA-DR is matched, HLA-DQ also is matched because of linkage disequilibrium, but this is not always the case [27]. In addition, the DQ (and DP) molecules consist of two chains (α and β) both of which are polymorphic and can exist in cis and trans isomers [21]. Therefore, there are four possible combinations of HLA-DQ which potentially complicate incorporating HLA-DQ matching in kidney matching schemes. In adult
registry studies, Lim et al. recently showed that HLA-DQ MM increased the likelihood of acute rejection and ABMR (all patients in ANZDATA) [27]. HLA-DQ MM alone was not a risk factor for allograft loss but the combination of HLA-DR and DQ MM had the worst outcome [27, 28]. Incorporating HLA-DQ MM information in future registry studies will further elucidate the importance of HLA class II versus class I matching.

Kidney donor quality

Expanded criteria donors (ECD) are defined as donors over 60 years or over 50 years of age with at least two risk factors of hypertension, serum creatinine > 1.5 mg/dl or death by cerebrovascular accident. ECD carry a higher risk of allograft failure and are not commonly used for paediatric recipients [29]. The risk factor of donor age as a marker of kidney quality has been widely studied [14, 16, 19, 30]. The importance of donor age was exemplified by the ‘Share 35’ kidney allocation policy in the USA which was implemented in November 2005. ‘Share 35’ gave absolute priority for donors under 35 years to be allocated to paediatric recipients, regardless of HLA matching. This resulted in reduced time to transplantation for children on the deceased donor waiting list and impacted clinicians performing less living donor transplants which could also increase sensitisation in subsequent transplants. Gritsch et al. examined the data for 8 years prior to ‘Share 35’ and showed that donors over 35 years of age had a relative risk of allograft loss of 1.32 compared with donors under 35 years of age at 5-year follow-up and the effect was independent of HLA MM [31]. Therefore, they concluded that a good quality donor outweighs the benefit of HLA matching. A similar analysis was performed by Foster et al. but including patients up to 21 years of age [14]. To study the interaction between donor age and HLA MM, they created stratified groups based on a hypothetical patient. There was no effect of HLA MM on DD under 35 years of age but both HLA MM and donor age increased the risk of allograft failure with DD above 35 years of age. This was corroborated by the 2010 CTS analysis which also showed donors up to 49 years of age had equal outcomes [16]. Of note, follow-up analysis was limited to 5 years in these studies and the effects of donor age and HLA MM could diverge with longer follow-up.

The prognosis from DD under 10 years of age is worse due to increased risk of surgical complications including thrombosis, rejection and hyperfiltration injury [30]. The donor age effect is less marked in LD and allograft survival outcomes are comparable due to full evaluation of LD for fitness to donate. Outcomes of donation from grandparents are also comparable with parents [32]. There is therefore no strict age cutoff for LD providing there is careful donor assessment.

Does HLA MM matter more than quality? This cannot be answered by multivariate analyses as each factor is assessed with an average taken of all the other factors (proportional hazards assumption). When assessing HLA MM, the average donor age and other co-variates are calculated, and when assessing donor age, the average HLA MM is calculated. It does not compare HLA MM for each donor age category and vice versa. Therefore, the analysis of HLA MM and donor age can only be performed by creating categories of each combination as performed by Foster as mentioned above [14]. In addition, the effect of donor age is not linear as there is a ‘U-shaped’ effect of donor age in DD, with high risk for donors under 10 years of age and a gradual increase in risk with increasing donor age [30]. ERA-EDTA registry data showed gradual increase in the HR with donor age but the risk increased markedly after donors above 50 years of age. Studies that use donor age as a linear co-variate will potentially underestimate its effect.

Donor age alone does not fully capture information about donor quality. Donors are now assigned a donor score which is the kidney donor profile index (KDPI) in USA which consists of ten different factors [33]. HLA matching is accounted for by giving additional points for full HLA match (0 MM) and if not fully matched, points for HLA-DR matching. Early results are promising with improved 1-year allograft survival which are mainly improvements in the period early post-transplant [34].

Living versus deceased donors

Renal allograft survival is improved for recipients of LD compared with DD in most registry data. There are similar outcomes in general between older LD and DD [14]. Well-matched (0 to 3 MM) older LD have better allograft survival than poorly matched (4 to 6 MM) younger DD [14]. The majority of LD in paediatrics are from parents and first-degree relatives and are therefore haploid MM (0 to 3 MM). In addition, the quality of kidney is controlled as donors undergo strict donor assessment, albeit that higher risk LD (e.g. hypertensive donors) is now considered even for paediatric recipients. Cold ischaemia time and ischaemic reperfusion injury are significantly reduced resulting in markedly less delayed graft function. The effect of HLA MM therefore is unsurprisingly stronger in LD and there is a significant increase from the 1 to 3 MM than from the 4 to 6 MM. The question therefore arises, what is the best practice for 4 to 6 MM LD? In the most recent UNOS analysis, LD with 4 to 6 MM lost their LD advantage and had similar allograft survival for 0 to 3 MM DD [15]. Comparing with a more selective group of 0 to 1 MM DD, poorly matched 4 to 6 MM had worse allograft survival (HR 1.36, 1.09–1.69, p = 0.006) [17] (Fig. 2). Therefore, one must weigh the outcomes of a poorer match LD against the matchability or the probability of being
successful in obtaining a better matched DD which may have additional implications for children on dialysis. This is potentially the case if grandparents or other extended relatives are being considered as LD. However, it is increasingly common in practice to put those donor-recipient pairs forward for the national living donor kidney sharing schemes.

**Long-term renal allograft survival**

At present, the aim is for children to receive a renal transplant with good patient and allograft survival rates with the potential for pre-emptive re-transplantation in the future. There are paediatric renal transplant recipients who become adults with functioning renal allograft lasting more than 20 years [35–37]. However, there are no defining predictors for those long-term survivors, although these patients tended to have better HLA matching, younger donors and LD (as opposed to DD) donors. The effect of HLA matching becomes more pronounced over the years so for transplants that survive longer than 15 years, the Kaplan-Meier curves became more widely separated as demonstrated from UNOS data [15]. The median survival for 0 MM was 25 years compared with 20 years for 1 MM, 18 years for 2 MM, 15 years for 3 MM and 12 years for higher MM [15]. Allograft loss is primarily due to chronic immune injury and accounts for 50% of allograft losses followed by a distant second cause of disease recurrence (8%) [38]. There is still a significant risk of rejection even with modern immunosuppression, particularly ABMR which can present with a low-grade indolent course [22].

**Effects of HLA matching beyond the first transplant**

Children with kidney transplants face a lifetime on immunosuppression. Morbidity and mortality are now mainly due to side effects of immunosuppression rather than renal failure itself [5, 38]. The cumulative incidence of cancers becomes significantly high after 25 years of transplant life; 27% for all cancers in the ANZDATA cohort and 22% in one Dutch study [39, 40]. In addition, 30% develop a second cancer within 2 years of the first cancer [40]. Squamous and basal cell skin cancers were the most predominant type followed by non-Hodgkin lymphoma (NHL)/post-transplant lymphoproliferative disorder (PTLD) and cervical cancers which may be preventable through HPV vaccination [41]. There was a bimodal distribution of cancer incidence, with a peak of 6.6 years for NHL/PTLD and 14.8 years for all others. The standardised incidence ratio for non-skin cancers was 8.23 (CI 6.9–9.7) compared with the healthy population and the risk of cancer was equivalent to a population 25 to 30 years older [39]. The risk of cancer increased with the length of time post-transplant without any significant differences between immunosuppression regimes [39, 40, 42]. The risk of PTLD was found to be associated with HLA-DR MM in one study but not corroborated by other studies [16, 39]. It would therefore be ideal to develop immunosuppression minimisation strategies based on HLA matching and clinical biomarkers.

Allograft failure also impacts waiting times for subsequent re-transplants [43, 44]. HLA sensitisation rates increased after allograft failure depending on the level of HLA MM [43]. Patients with 2 DR MM waited 23 months compared with 19 months for 0 to 1 HLA-DR MM patients [44]. In addition, a higher proportion of patients with 2 HLA-DR MM were still on the waiting list and had 32% less chance of being successfully transplanted. The HLA-DR MM of the first transplant also reduced survival in the second transplant and this result has been corroborated in a number of adult studies [7, 44]. Importantly though, HLA-DR MM due to a LD at the first transplant had no negative outcomes in the second transplant [44].

Foster et al. looked at retransplant rates in UNOS patients under 21 years of age between 1988 and 2009 [45]. HLA matchability was calculated so patients were not penalised twice for getting poor MM transplants because of difficulty matching the first transplant and also subsequent transplants. Socioeconomic status was also included in the model. In the first transplant, recipients with 4 to 6 HLA MM did worse compared with 0 to 1 and 2 to 3 MM but the effect only became more apparent 10 years post-transplant. This was significant for both HLA class I and class II MM. Increasing MM in the first transplant increased waiting time for the second transplant. The median waiting time for a previous 0 to 1 MM was 2 years compared with 3 years for 2 to 3 MM and 5 years for 4 to 6 MM [45].
Future HLA matching strategies

Historically, HLA typing was performed using serological methods. HLA antibodies were identified in sensitised individuals (e.g. multiparous women and these antisera were used as HLA typing reagents). HLA antibodies were therefore clinically significant but the number of HLA types was limited by the available antibodies. HLA typing is now performed using molecular methods but high-resolution typing is not routinely used in typing donors and recipients for solid organ transplantation. Furthermore, all HLA specificities and loci are not individually considered in determining the level of an HLA match. Consequently a zero mismatch might not be fully matched. This can partly explain some of the benefits of LD versus DD. In a LD from direct family members, one can be certain of the HLA matches and the maximum actual mismatch is a haplotype 50% mismatch.

Computational three-dimensional reconstructions of HLA molecules can be derived from the molecular types, although high-resolution HLA typing is required. Amino acids might be contiguous on the HLA molecule but adjacent to different amino acids in three-dimensional space. The eplet analysis through HLAMatchmaker takes this spatial configuration into account in defining three amino acid sequences as epitopes on the surface of the HLA molecule [46, 47]. HLA MM is performed based on a score of potential eplet mismatches between donor and recipient rather than limited to 0/1 for each allele. The eplet score for HLA-DR was shown to be a better predictor of the development of HLA-DR antibodies [48, 49]. Some patients with 0 HLA-DR MM had high eplet MM and vice versa. The tertiary HLA structure can also be computed based on the electrostatic interaction between amino acid molecules (EMS-3D score) [47, 50, 51]. The electrostatic forces are also postulated to affect affinity binding of antibody to HLA epitopes. Increasing EMS-3D was strongly and independently associated with an incremental increase in the risk of allograft failure in the adult cohort of 10,726 first DD patients in the UK Transplant Registry [52]. HLA matching will become more refined in the future, which would potentially change how organs are allocated. Matching would no longer be a dichotomous result but be based on a score. There would then be a threshold risk (e.g. 11/41 in the Wiebe et al. analysis) for the development of HLA antibodies or rejection [48].

Conclusion

While the incidence of end-stage kidney disease (ESKD) is increasing in adults, the number of new paediatric patients in developed countries has plateaued [53]. Children represent only a small proportion of patients in renal transplantation programs. There needs to be consideration of the risks of sensitisation and re-transplantation in designing new kidney offering schemes for potential future paediatric renal transplant recipients. Kidney donor quality is fundamentally important, particularly for DD and also for LD. The medium- to long-term allograft survival for DD is highly influenced by donor quality. Allografts with very long-term survival though (>15 years) are associated with better HLA matching. The main cause of allograft failure is still chronic immune injury despite advances in immunosuppression. Even patients with 0 HLA-A, HLA-B and HLA-DR MM are at risk of rejection due other HLA MM and other minor antigens.

The evidence supports LD with improved allograft survival compared with DD. Even poorly [4 to 6] MM LD have comparable outcomes with DD recipients [14]. The question is “Can a better HLA match of equal donor quality be obtained?” whether as a 0 to 1 MM DD or through a paired exchange scheme. HLA MM is not currently the main reason for entering into paired exchange schemes [54]. However, the chances of matching would increase markedly if the numbers of potential donors increase. A chain of kidney donors has also been triggered by a DD initiating the chain and the final LD donating back into the waiting list [55]. The scenario of a poor MM LD is less common in paediatrics compared with adults (e.g. spousal donation). An online calculator based on the SRTR data is available for estimating survival times where multiple LD options are available [56]. The key to appreciating waiting times is knowing the matchability score of the patient and understanding the local kidney offering scheme. Ultimately, the decision for the type of transplant and degree of acceptable HLA MM depends on each patient circumstance and needs to take into account the added complications of ESKD and dialysis.

Early planning for transplantation is critical in paediatric practice and a ‘Transplant First’ approach remains a laudable aim [9, 57]. HLA matching is valuable for very long-term outcomes, reducing HLA sensitisation and in improving access to re-transplantation. HLA matching is crucial for reducing the ‘dialysis-free period’ over the lifetime of paediatric patients.

Multiple-choice questions (answers following the references)

1. Which of the following is true regarding living donation (choose one)?
   a) Overall, living donors last longer than deceased donors.
   b) A living donor with 4 MM is better than a deceased donor with 1 MM of the same age.
   c) A living donor with haplotype MM including 1 DR MM has worse outcomes in the second transplant compared to a 0 HLA-DR MM deceased donor at the time of first transplant.
d) A healthy 60 year old living donor with 3 HLA MM has worse allograft survival compared to an equivalently matched 40 year old living donor.

2. Which of the following is true regarding deceased donation (choose one)?

a) There is no effect of HLA matching in young donors (<35 years of age) for 5 year allograft survival.

b) Donors less than <5 years have similar survival to older donors.

c) Class I HLA MM does not affect kidney transplant outcome.

d) When deciding whether to accept deceased donors, one should always wait for a favourable (≤3) HLA MM.

3. Which of the following is true regarding long term allograft survival (choose one)?

a) Class II HLA MM is associated with antibody mediated rejection.

b) Patients who are matched for HLA-DR will always be matched for HLA-DQ.

c) Median allograft survival for a 0 MM transplant is 15 years.

d) 0 MM deceased donors do not reject.

4. Which of the following is true regarding long-term patient morbidity (choose one)?

a) Results of registry studies can be readily applied to populations in different countries.

b) MMF is a risk factor for developing cancer in transplant recipients.

c) HLA-DR MM is a large risk factor for developing posttransplant lymphoproliferative disease.

d) HLA MM increases risk of sensitisation after allograft loss and increases waiting times for subsequent transplants.

5. Choose the transplant with the best expected allograft survival.

a) LD from 60 year old grandmother who is a 4 HLA MM

b) LD from 30 year old father who is 3 HLA MM

c) DD from a 30 year old 3 HLA MM who died from a road traffic accident

d) DD from a 50 year old 1 HLA MM who was hypertensive and died of a cerebral vascular accident

1. a; 2. a; 3. a; 4. d; 5. b

Acknowledgements All research at Great Ormond Street Hospital NHS Foundation Trust and UCL Great Ormond Street Institute of Child Health is made possible by the NIHR Great Ormond Street Hospital Biomedical Research Centre.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Disclaimer The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Leeson S, Desai SP (2015 Jan) Medical and ethical challenges during the first successful human kidney transplantation in 1954 at Peter Bent Brigham Hospital. Boston Anesth Analg 120(1):239–245

2. Park I, Terasaki P (2000) Origins of the first HLA specificities. Hum Immunol [Internet] 61(3):185–189 Available from: http://www.sciencedirect.com/science/article/pii/S0198885999001548

3. Patel R, Terasaki PI (1969 Apr) Significance of the positive cross match test in kidney transplantation. N Engl J Med 280(14):735–739

4. Azzi JR, Sayegh MH, Mallat SG (2013) Calcineurin inhibitors: 40 years later, can ‘t live without … J Immunol [Internet]. 191(12):5785–5791. Available from: http://www.jimmunol.org/cgi/doi/10.4049/jimmunol.1390055

5. Kim JJ, Marks SD (2014 Jan) Long-term outcomes of children after solid organ transplantation. Clinics [Internet] 69(Suppl 1):28–38 Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3884158/

6. Mumford L, Maxwell H, Ahmad N, Marks SD, Tizard EJ (2019) The impact of changing practice on improved outcomes of paediatric renal transplantation in the United Kingdom: a twenty-five year review. Transpl Int. 2019;submitted for publication

7. Zachary AA, Leffell MS (2016) HLA mismatching strategies for solid organ transplantation - a balancing act. Vol. 7, Front Immunol. p. 1–14

8. Harambat J, Van Straalen KJ, Schaefer F, Grenda R, Jankauskiene A, Kostic M et al (2013) Disparities in policies, practices and rates of pediatric kidney transplantation in Europe. Am J Transplant [Internet] 13(8):2066–2074 Available from: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed15&NEWS=N&AN=52608693

9. Amaral S, Sayed BA, Kutner N, Patzer RE (2016) Preemptive kidney transplantation is associated with survival benefits among pediatric patients with end stage renal disease. Kidney Int [Internet] 90(5):1100–1108 Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5072842/
10. RE G, NA D, MB L (2014) Analysis, interpretation, and reporting of registry data to evaluate outcomes. In: Registries for evaluating patient outcomes: a user’s guide [Internet] [Internet]. 3rd ed. Rockville (MD): Agency for Healthcare Research and Quality (US); Available from: https://www.ncbi.nlm.nih.gov/books/NBK208602/

11. Wang JH, Skeans MA, Israni AK (2016) Current status of kidney transplant outcomes: dying to survive. Adv Chronic Kidney Dis [Internet] 23(5):281–286. https://doi.org/10.1053/j.ackd.2016.07.001

12. Yost SE, Kaplan B (2013) Comparing kidney transplant outcomes: cavaets and lessons. Nephrol Dial Transplant 28(1):9–11

13. Gjertson DW, Cecka JM (2001) Determinants of long-term survival of pediatric kidney grafts reported to the United Network for Organ Sharing kidney transplant registry. Pediatr Transplant [Internet] 5(1):5–15 Available from: http://www.ncbi.nlm.nih.gov/pubmed/11260482

14. Foster BI, Dahhou M, Zhang X, Platt RW, Hanley JA (2013) Relative importance of HLA mismatch and donor age to graft survival in young kidney transplant recipients. Transplantation. 96(5):469–475

15. Williams RC, West LJ, Opelz G (2018) The risk of failure with HLA mismatch and recipient age in first pediatric (≤18 years) kidney transplants. Transplant Direct [Internet] 4(7):e365 Available from: http://insights.ovid.com/crossref?an=01845228-20180700-00002

16. Opelz G, Döhler B (2010) Pediatric kidney transplantation: analysis of donor age, HLA match, and posttransplant non-Hodgkin lymphoma: a collaborative transplant study report. Transplantation. 90(3):292–297

17. Opelz G, Döhler B, Middleton D, Süsal C (2017) HLA matching in pediatric kidney transplantation: HLA poorly matched living donor transplants versus HLA well-matched deceased donor transplants. Transplantation. 101(11):2789–2792

18. Marlais M, Hudson A, Pankhurst L, Fuggle SV, Marks SD (2016) Living donation has a greater impact on renal allograft survival than HLA matching in pediatric renal transplant recipients. Transplantation. 100(12):2717–2722

19. Tmkra P, McTaggart SJ, Francis A (2018) The impact of donor/recipient age difference and HLA mismatch on graft outcome in pediatric kidney transplantation. Pediatr Transplant [Internet]. (February):e13265. https://doi.org/10.1111/petr.13265

20. Connolly JK, Dyer PA, Martin S, Parrott NR, Pearson RC, Johnson RW (1996 Mar) Importance of minimizing HLA-DR mismatch and cold preservation time in cadaveric renal transplantation. Transplantation 61(5):709–714

21. Tambur AR (2016) HLA-DQ antibodies: are they real? Are they relevant? Why so many? Current Opinion in Organ Transplantation 21:441–446

22. Kim JJ, Balasubramanian R, Michaelides G, Wittenhagen P, Sebire NJ, Mamode N, et al. (2014) The clinical spectrum of de novo donor-specific antibodies in pediatric renal transplant recipients 2350–2358

23. Pober JS, Collins T, Gimbrone MA Jr, Cotran RS, Gitlin JD, Fiers W et al (1983) Lymphocytes recognize human vascular endothelial and dermal fibroblast la antigens induced by recombinant immune interferon. Nature [Internet] 20(305):726. https://doi.org/10.1038/305726a

24. Fuggle SV, McWhinnie DL, Morris PJ (1987) Precise specificity of induced tubular HLA-class II antigens in renal allografts. Transplantation 44(2):214–220

25. Fuggle SV, McWhinnie DL, Chapman JR, Taylor HM, Morris PJ (1986) Sequential analysis of HLA-class II antigen expression in human renal allografts. Induction of tubular class II antigens and correlation with clinical parameters. Transplantation 42(2):144–150

26. Nocera A, Tagliamacco A, Cioni M, Innocente A, Fontana I, Barbano G et al (2017) Kidney intragraft homing of de novo donor-specific HLA antibodies is an essential step of antibody-mediated damage but not per se predictive of graft loss. Am J Transplant 17(3):692–702

27. Lim WH, Chapman JR, Coutes PT, Lewis JR, Russ GR, Watson N et al (2016) HLA-DQ mismatches and rejection in kidney transplant recipients. Clin J Am Soc Nephrol 11(5):875–883

28. Leaephorn N, Pena JRA, Thamcharoen N, Khankin EV, Pavlakis M, Cardarelli F (2018) Article HLA-DQ mismatching and kidney transplant outcomes. Clin J Am Soc Nephrol 13:763–771

29. El Ene Querard A-H, Foucher Y, Combescure C, Dantan E, Larmet D, Lorent M et al (2016) Comparison of survival outcomes between Expanded Criteria Donor and Standard Criteria Donor kidney transplant recipients: a systematic review and meta-analysis. Transpl Int 29:403–415

30. Chesnaye NC, Van Stralen KJ, Bonthuis M, Groothoff JW, Harambat J, Schafer F et al (2017) The association of donor and recipient age with graft survival in paediatric renal transplant recipients in a European Society for Paediatric Nephrology/European Renal Association-European Dialysis and Transplantation Association Registry study. Nephrol Dial Transplant 32(11):1949–1956

31. Gritsch HA, Veale JL, Leichtman AB, Guidinger MK, Magee JC, McDonald RA et al (2008) Should pediatric patients wait for HLA-DR-matched renal transplants? Am J Transplant 8(10):2056–2061

32. Simpson CM, McTaggart SJ, Sterne JAC, Walker RG, Powell HR, Jones CL (2005) Grandparent donors in paediatric renal transplantation. Pediatr Nephrol [Internet] 20(11):1636–1641. https://doi.org/10.1007/s00467-005-2002-x

33. Israni AK, Salkowski N, Gustafson S, Snyder JJ, Friedewald JJ, Forrnica RN et al (2014 Aug) New national allocation policy for deceased donor kidneys in the United States and possible effect on patient outcomes. J Am Soc Nephrol 25(8):1842–1848

34. Hart A, Gustafson SK, Skeans MA, Stock P, Stewart D, Kasiske BL et al (2017 Jan) OPTN/SRTR 2015 Annual Data Report: early effects of the new kidney allocation system. Am J Transplant 17(Suppl 1):S54–S63

35. Bererhi L, Pellet N, Zuber J, Anglicheau D, Kreis H, Legendre C et al (2012) Clinical and immunological features of very long-term survivors with a single renal transplant. Transpl Int 25(5):545–554

36. Traynor C, Jenkinson A, Williams Y, O’Kelly P, Hickey D, Denton M et al (2012) Twenty-year survivors of kidney transplantation. Am J Transplant 12(12):3289–3295

37. Traynor C, Conlon PJ (2013) Very long-term survivors of kidney transplantation. Transpl Int [Internet] 26(2):e8–e9 Available from: http://www.ncbi.nlm.nih.gov/pubmed/23230987

38. Emmes Corporation (2014) Annual transplant report. Collab Stud NAPRTCS [Internet]. 2014;102. Available from: https://www.emmes.com/study/cedar/annualrept2014.pdf

39. Francis A, Johnson DW, Craig JC, Wong G (2017) Incidence and predictors of cancer following kidney transplantation in childhood. Am J Transplant 17(10):2650–2658

40. van Amstel SP, Vogelzang JI, Starink MV, Jager KJ, Groothof FW (2015) Long-term risk of cancer in survivors of pediatric ESRD. Clin J Am Soc Nephrol 10(12):2198–2204

41. Lehtinen M, Lagerstedt C, Luostariinen T, Eriksson T, Apter D, Harjula K et al (2017) Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia endpoint-registry-based follow-up of three cohorts from randomized trials. BMJ Open 7(8):e015867

42. Tincakam KJ, Rose C, Haribaran S, Gill J (2016) Re-examining risk of repeated HLA mismatch in kidney transplantation. J Am Soc Nephrol [Internet]:2833–41. Available from: http://www.jasn.org/cgi/doi/10.1618/ASN.2015060626
43. Meier-Kriesche HU, Scornik JC, Susskind B, Rehman S, Schold JD (2009) A lifetime versus a graft life approach redefines the importance of HLA matching in kidney transplant patients. Transplantation 88(1):23–29

44. Gralla J, Tong S, Wiseman AC (2013) The impact of human leukocyte antigen mismatching on sensitization rates and subsequent retransplantation after first graft failure in pediatric renal transplant recipients. Transplantation 95(10):1218–1224

45. Foster BJ, Dahhou M, Zhang X, Platt RW, Smith JM, Hanley JA (2014) Impact of HLA mismatch at first kidney transplant on lifetime with graft function in young recipients. 876–885

46. Duquesnoy RJ, Askar M (2007) HLAMatchmaker: a molecularly based algorithm for histocompatibility determination. V. Eplet Matching for HLA-DR, HLA-DQ, and HLA-DP. Hum Immunol [Internet] 68(1):12–25 Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2527859/

47. Copley HC, Elango M, Kosmoliaptsis V (2018) Assessment of human leukocyte antigen immunogenicity: current methods, challenges and opportunities. Curr Opin Organ Transplant 23:477–485

48. Wiebe C, Rush DN, Nevins TE, Birk PE, Blydt-Hansen T, Gibson IW et al (2017) Class II eplet mismatch modulates tacrolimus trough levels required to prevent donor-specific antibody development. J Am Soc Nephrol [Internet] 28:1–10 Available from: www.jasn.org

49. Wiebe C, Kosmoliaptsis V, Pochinco D, Taylor CJ, Nickerson P (2018) A comparison of HLA molecular mismatch methods to determine HLA immunogenicity. Transplantation 102(8):1338–1343

50. Kosmoliaptsis V, Dafforn TR, Chaudhry AN, Halsall DJ, Bradley JA, Taylor CJ (2011 Nov) High-resolution, three-dimensional modeling of human leukocyte antigen class I structure and surface electrostatic potential reveals the molecular basis for alloantibody binding epitopes. Hum Immunol 72(11):1049–1059

51. Kosmoliaptsis V, Sharples LD, Chaudhry AN, Halsall DJ, Bradley JA, Taylor CJ (2011 Jan) Predicting HLA class I alloantigen immunogenicity from the number and physicochemical properties of amino acid polymorphisms. Transplantation 91(2):183–190

52. Kosmoliaptsis V, Mallon D, Fuggle S, Johnson R, Watson C, Bradley J, et al. (2017) A novel computational HLA matching algorithm for improving donor-recipient histocompatibility and graft outcomes after kidney transplantation. [abstract]. Am J Transpl [Internet]. 17 (suppl. Available from: https://atcmeetingabstracts.com/abstract/a-novel-computational-hla-matching-algorithm-for-improving-donor-recipient-histocompatibility-and-graft-outcomes-after-kidney-transplantation/. Accessed August 29, 2018

53. Harambat J, Van Stralen KJ, Kim JJ, Tizard EJ (2012) Epidemiology of chronic kidney disease in children. Pediatr Nephrol:363–373

54. Kute VB, Prasad N, Shah PR, Modi PR (2018 Jun 28) Kidney exchange transplantation current status, an update and future perspectives. World J Transplant [Internet] 8(3):52–60 Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033740/

55. Melcher ML, Roberts JP, Leichtman AB, Roth AE, Rees MA (2016 May 9) Utilization of deceased donor kidneys to initiate living donor chains. Am J Transplant [Internet]. 16(5):1367–1370 Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4844828/

56. Ashby VB, Leichtman AB, Rees MA, Song PX-K, Bray M, Wang W et al (2017 Jul 7) A kidney graft survival calculator that accounts for mismatches in age, sex, HLA, and body size. Clin J Am Soc Nephrol [Internet] 12(7):1148–1160 Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5498352/

57. Barclay M, Burnapp L (2013) Transplant First: Timely Listing for Kidney Transplantation [Internet]. Available from: https://www.england.nhs.uk/improvement-hub/wp-content/uploads/sites/44/2017/11/Transplant-First-Timely-Listing-for-Kidney-Transplantation.pdf

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.